# US 2026/0091046 A1 · Method For Treatment Of Pancreatic Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091046 A1
- Document ID: US20260091046A1
- Status: Published application
- Kind: A1
- Application number: 18/905,128
- Filed: 2024-10-02
- Published: 2026-04-02
- Earliest claimed: 2024-10-02
- Assignees: Cannabis Bioscience International Holdings Inc
- Applicants: Cannabis Bioscience International Holdings, Inc.
- Inventors: Dante Picazo; Stephanie Dona Hartmann; Rosangel Del Valle Andrades Fuentes; Nancy Paola Duarte Delgado; Nancy Rodrigues Das Fontes; Ana Maria Maldonado Vacca
- Web page: https://patentgrep.com/patent/US20260091046A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/50: Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)}
- A61K 31/015: carbocyclic
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Aspects of the disclosure provide a formulation for treating advanced pancreatic cancer, comprising a combination of a cannabinoid, a terpene, and a flavonoid. To enhance bioavailability and targeted delivery, the formulation is incorporated into a nanoplatform, such as a nanoemulsion, optimizing absorption and delivery to cancer cells. The nanoparticle-based composition specifically targets advanced stages of pancreatic cancer, aiming to inhibit tumor progression and improve clinical outcomes.

## Claims

### Claim 1

A composition for treatment of pancreatic cancer, comprising:
an active principle; and
a stabilizing solubilizing agent, wherein the active principle comprises a cannabinoid, a terpene, and a flavonoid.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the active principle is present in a concentration in a range of 50% to 71%, and the stabilizing solubilizing agent is present in a concentration in a range of 0.1% to 5%.

### Claim 3 (depends on 2)

The composition according to claim 2, wherein the cannabinoid is present in a concentration in a range of 10% to 15%, the terpene is present in a concentration in a range of 25% to 28%, and the flavonoid is present in a concentration in a range of 25% to 28%.

### Claim 4 (depends on 3)

The composition according to claim 3, wherein the cannabinoid comprises THC, THCV, CBD, CBG, and CBC, the terpene comprises limonene and the flavonoid comprises kaempferol.

### Claim 5 (depends on 4)

The composition according to claim 4, wherein the THC is present in a concentration in a range of 1% to 1.45%, the THCV is present in a concentration in the range of 1.5% to 2.25%, the CBD is present in a concentration in a range of 4.5% to 5.5%, the CBG is present in a concentration in the range of 3.5% to 4.5%, the CBC is present in a concentration in a range of 1% to 1.45%, the limonene is present in a concentration in a range of 25% to 28% and the kaempferol is present in a concentration in a range of 25% to 28%.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the composition is a nanoemulsion formulation comprising nanoparticles.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein the stabilizing solubilizing agent is PEG-400.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein the nanoparticles have an average size of less than 200 nm.

### Claim 9 (depends on 1)

The composition according to claim 1, wherein a nanoemulsion formulation is designed to provide a controlled release of the cannabinoids, the terpenes, and the flavonoids.

### Claim 10 (depends on 1)

The composition according to claim 1, wherein the composition is suitable for oral administration in capsule form.

### Claim 11

A method for treating one of metastatic and locally advanced pancreatic cancer in a human individual, comprising:
administering an effective concentration of a composition, wherein the composition comprises
an active principle and
a stabilizing solubilizing agent, wherein the active principle comprises a cannabinoid, a terpene, and a flavonoid.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the human individual is selected for treatment based on at least one of: i) Stage III pancreatic cancer, ii) Stage IV metastatic pancreatic cancer, iii) Pancreatic cancer in the pancreatic head, iv) More than three metastatic sites, v) Patients under palliative care.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the pancreatic cancer is pancreatic adenocarcinoma.

### Claim 14 (depends on 12)

The method of claim 12, wherein the individual has biomarker results for CA19-9.

### Claim 15 (depends on 11)

The method according to claim 11, wherein the effective concentration is administered as one daily capsule containing 1270 mg of active principle for Stage Ill patients, and two daily capsules for Stage IV patients over an 8-week period.

### Claim 16 (depends on 11)

The method of claim 11, wherein the effective concentration of active principle is in the range of 1143 mg to 1397 mg.

### Claim 17 (depends on 11)

The method according to claim 11, wherein the administering of the effective concentration of the composition of targets at least one of a pancreatic head and surrounding tissue.

### Claim 18

A method for producing a pharmaceutical composition for treating pancreatic cancer, comprising: incorporating a cannabinoid, a terpene, and a flavonoid into a nanoplatform comprising a stabilizing solubilizing agent.

### Claim 19 (depends on 18)

The method of claim 18, where the nanoplatform is a nanoemulsion comprising PEG-400 as a stabilizing solubilizing agent, in a form of nanoparticles.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the nanoparticles have an average size of less than 200 nm.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the formulation is tailored to provide a controlled release of the cannabinoids, terpenes, and flavonoids, and wherein the composition is administered in an oral dosage form selected from a group consisting of capsules, tablets, or liquid solutions.
